How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer.

Oncol Ther · 2021 · PMC8593140 · PMID 34057699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the between-group differences did not reach statistical significance in these patient subgroups, the cumulative incidence of CNS recurrence was numerically lower in the neratinib arm at 5 years (0.7% vs. 2.1% with placebo).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.